A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1α through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma

Cancer Research

Volumn 65, Issue 16, 2005, Pages 7267-7275

  Das, Bikul ^a,b   Yeger, Herman ^a,b   Tsuchida, Rika ^a   Torkin, Risa ^a   Gee, Matthew F W ^b   Thorner, Paul S ^a,b   Shibuya, Masabumi ^c   Malkin, David ^a,b   Baruchel, Sylvain ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BASIC FIBROBLAST GROWTH FACTOR; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; SMALL INTERFERING RNA; URSOLIC ACID; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HYPOXIA; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

CELL HYPOXIA; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOPRECIPITATION; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEUROBLASTOMA; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 23844450576     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4575     Document Type: Article

References (54)

1. Yokoi K, Fidler I. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004;10:2299-306.
2. Harris A. Hypoxia: a key regulatory factor in tumor growth. Nat Rev Cancer 2002:2:38.
3. Semenza G. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
4. Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin D, Moore MA. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 2004;104:2893-902.
5. Steiner HH, Karcher S, Mueller MM, Nalbantis E, Kunze S, Herold-Mende C. Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neurooncol 2004;66:129-38.
6. Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-β-D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004;103577-85.
7. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 2004;103:3883-9.
8. Lee Y, Bone N, Strege A, Shanafelt T, Jelinek D, Kay N. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004;104:788-94.
9. Qi L, Robinson WA, Brady BM, Glode LM. Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors. Anticancer Res 2003;23:3917-22.
10. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193: 468-75.
11. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97:427-34.
12. Bates RC, Goldsmith JD, Bachelder RE, et al. Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr Biol 2003;13:1721-7.
13. Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A, Freeman MR. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 2001;159:651-9.
14. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10-4.
15. Langer I, Vertongen P, Perret J, Fontaine J, Atassi G, Robberecht P. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. Med Pediatr Oncol 2000;34:386-93.
16. Das B, Yeger H, Baruchel H, Freedman M, Koren G, Baruchel S. In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity. Implications in cancer chemotherapy. Eur J Cancer 2003;39:2556-65.
17. Jogi A, Ora I, Nilsson H, et al. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA 2002;99:7021-6.
18. Dimitroulakos J, Squire J, Pawlin G, Yeger H. NUB-7: a stable I-type human neuroblastoma cell line inducible along N- and S-type cell lineages. Cell Growth Differ 1994;5:373-84.
19. Feldkamp M, Lau N, Rak J, Kerbel R, Guha A. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int J Cancer 1999;81:118-24.
20. Fotsis T, Breit S, Lutz W, et al. Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells. Eur J Biochem 1999;263:757-64.
21. Gee MFW, Tsuchida R, Malkin D. Expression of vascular endothelial growth factor (VEGF) and VEGF tyrosine-kinase receptor expression in rhabdomyosarcoma [abstract]. Proc Am Assoc Cancer Res 2003;44:842.
22. Beierle EA, Dai W, Langham MR Jr, Copeland EM III, Chen MK. Expression of VEGF receptors in cocultured neuroblastoma cells. J Surg Res 2004;119: 56-65.
23. Relds R, Lancaster M. Dual-attribute continuous monitoring of cell proliferation/cytotoxicity. Am Biotechnol Lab 1993;11:48-50.
24. Carrasco R, Stamm N, Patel B. One-step cellular caspase-3/7 assay. Biotechniques 2003;34:1064-7.
25. Torkin R, Lavoie JF, Kaplan DR, Yeger H. Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma Mol Cancer Ther 2005;4:1-11.
26. Minet E, Arnould T, Michel G, et al. ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett 2000;468:53-8.
27. Nagamatsu S, Komhauser J, Burant C, Seino S, Mayo K, Bell G. Glucose transporter expression in brain. cDNA sequence of mouse GLUT3, the brain facilitative glucose transporter isoform, and identification of sites of expression by in situ hybridization. J Biol Chem 1992;267:467-72.
28. Chevalier S, Defoy J, Lacoste J, et al. Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis. Mol Cell Endocrinol 2002;189: 169-79.
29. Tahir S, Gu W, Zhang H, et al. Inhibition of farnesyl-transferase with A-176120, a novel and potent farnesyl pyrophosphate analogue. Eur J Cancer 2000;36:1161-70.
30. Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 1996;7:213-21.
31. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Oncol 2000;105:15-24.
32. Takahashi M, Matsui A, Inao M, Mochida S, Fujiwara K. ERK/MAPK-dependent PI3K/Akt phosphorylation through VEGFR-1 after VEGF stimulation in activated hepatic stellate cells. Hepatol Res 2003;26:232-6.
33. Kazi AS, Lotfi S, Goncharova EA, et al. Vascular endothelial growth factor-induced secretion of fibronectin is ERK dependent. Am J Physiol Lung Cell Mol Physiol 2004;286:L539-45.
34. Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998;17:2215-23.
35. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-20.
36. Cervinka M, Cerman J, Rudolf E. Apoptosis in Hep2 cells treated with etoposide and colchicine. Cancer Detect Prev 2004;28:214-26.
37. Erler T, Cawthorne C, Williams K, et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducibIe factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biology 2004;24:2875-89.
38. Beierle EA, Strande LF, Chen MK. VEGF upregulates Bcl-2 expression and is associated with decreased apoptosis in neuroblastoma cells. J Pediatr Surg 2002;37:467-71.
39. Baek J, Jang J, Kang C, Chung H, Kim N, Kim K. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 2000;19:4621-31.
40. Ballif B, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 2001;12:397-408.
41. Subbaramaiah K, Michaluart P, Sporn MB, Dannenberg AJ. Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Cancer Res 2000;60:2399-404.
42. Moeller B, Cao Y, Li C, Dewhirst M. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004;5:429-41.
43. Jonca F, Ortega N, Gleizes P-E, Bertrand N, Plouet J. Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor. J Biol Chem 1997;272:24203-9.
44. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
45. Graeber G, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996;379:88-90.
46. Tang N, Wang L, Esko J, et al. Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004;6:485-95.
47. Orecchia A, Lacal PM, Schietroma C, Morea V, Zambruno G, Failla CM. Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the α 5 β 1 integrin. J Cell Sci 2003;116:3479-89.
48. Hanahan D, Weinberg R. The hallmarks of cancer. Cell 2000;100:57-70.
49. Koch S, Mayer F, Honecker F, Schitternhelm M, Bokemeyer C. Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. Br J Cancer 2003;89:2133-9.
50. Teicher B. Hypoxia and drug resistance. Cancer Metastasis Rev 1994;13:139-68.
51. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
52. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur G, Himelstein B. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 2000;6:1900-8.
53. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25: 581-611.
54. Shishodia S, Majumdar S, Banerjee S, Aggarwal BB. Ursolic acid inhibits nuclear factor-κB activation induced by carcinogenic agents through suppression of IκBα kinase and p65 phosphorylation; correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res 2003;63:4375-83.